natgillin/translations-raw huggingface dataset:
Crixivan må ikke anvendes hos personer, som kan være overfølsomme (allergiske) over for indinavir eller nogen af de øvrige indholdsstoffer.
Crixivan should not be used in people who may be hypersensitive (allergic) to indinavir or any of the other ingredients.
Crixivan må ikke anvendes til patienter, som tager et eller flere af følgende lægemidler: • lægemidler, der nedbrydes på samme måde som Crixivan og er skadelige, hvis koncentrationen i blodet bliver for høj • amiodaron (anvendes mod uregelmæssig hjerterytme) • terfenadin og astemizol (anvendes til behandling af allergisymptomer – disse lægemidler kan udleveres uden recept) • cisaprid (anvendes til lindring af visse maveproblemer) • alprazolam, triazolam og midazolam, som indtages gennem munden (anvendes mod angst eller søvnbesvær) • pimozid (anvendes til behandling af psykiske sygdomme) • ergotderivater (anvendes mod migræne) • simvastatin og lovastatin (kolesterolsænkende midler) • rifampicin (anvendes til behandling af tuberkulose) • St John’ s perikum (et naturlægemiddel til behandling af depression)
Crixivan should not be used in patients who are taking any of the following medicines: • medicines that are broken down in the same way as Crixivan and are harmful at high levels in the blood; • amiodarone (used to correct irregular heartbeat); • terfenadine, astemizole (commonly used to treat allergy symptoms – these medicines may be available without a prescription); • cisapride (used to treat certain stomach problems); • alprazolam, triazolam, midazolam taken by mouth (used to treat anxiety or difficulty sleeping); • pimozide (used to treat mental illness); • ergot derivatives (used to treat migraine headache); • simvastatin, lovastatin (used to lower cholesterol in the blood); • rifampicin (used to treat tuberculosis); • St John ’ s wort (a herbal preparation used to treat depression).
2/ 3 Også når Crixivan anvendes sammen med andre lægemidler, bør forsigtighed udvises.
2/ 3 Caution is needed when Crixivan is taken at the same time as other medicines.
Den fuldstændige liste over disse lægemidler fremgår af indlægssedlen.
Additional restrictions apply when Crixivan is taken with ritonavir.
Den fuldstændige liste fremgår af indlægssedlen for ritonavir.
See the Package Leaflet provided with ritonavir for the full list.
Som med anden hiv- medicin kan patienter, der får Crixivan, få lipodystrofi (forandringer i kropsfedtets fordeling), osteonekrose (knoglevævsdød) eller immunreaktiveringssyndrom (infektionslignende symptomer, der skyldes, at immunsystemet genvinder sin funktion).
As with other anti-HIV medicines, patients taking Crixivan may also be at risk of lipodystrophy (changes in the distribution of body fat), osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).
Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Crixivan i kombination med antiretrovirale nukleosidanaloger til behandling af hiv- inficerede voksne, unge og børn over fire år opvejer risiciene.
The Committee for Medicinal Products for Human Use (CHMP) decided that Crixivan’ s benefits are greater than its risks in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults, adolescents, and children four years of age and older.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Crixivan.
The Committee recommended that Crixivan be given marketing authorisation.
Crixivan blev oprindeligt godkendt under "særlige omstændigheder", da der på godkendelsestidspunktet af faglige årsager kun forelå begrænsede oplysninger.
Crixivan was originally authorised under ‘ Exceptional Circumstances’, because, for scientific reasons, limited information was available at the time of approval.
Efter at firmaet havde forelagt de supplerende oplysninger, det var blevet anmodet om, blev de "særlige omstændigheder" ophævet den 8. april 1998.
As the company had supplied the additional information requested, the ‘ Exceptional Circumstances ’ ended on 8 April 1998.
Andre oplysninger om Crixivan:
Other information about Crixivan:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Crixivan til Merck Sharp & Dohme Limited den 4. oktober 1996.
The European Commission granted a marketing authorisation valid throughout the European Union for Crixivan to Merck Sharp & Dohme Limited on 4 October 1996.
Markedsføringstilladelsen blev fornyet den 4. oktober 2001 og den 4. oktober 2006.
The marketing authorisation was renewed on 4 October 2001 and on 4 October 2006.
Den fuldstændige EPAR for Crixivan findes her.
The full EPAR for Crixivan can be found here.
EU Nummer EU/ 1/ 96/ 024/ 001 EU/ 1/ 96/ 024/ 002 EU/ 1/ 96/ 024/ 003 EU/ 1/ 96/ 024/ 004 EU/ 1/ 96/ 024/ 005 EU/ 1/ 96/ 024/ 008 EU/ 1/ 96/ 024/ 010
EU/ 1/ 96/ 024/ 001 EU/ 1/ 96/ 024/ 002 EU/ 1/ 96/ 024/ 003 EU/ 1/ 96/ 024/ 004 EU/ 1/ 96/ 024/ 005 EU/ 1/ 96/ 024/ 008 EU/ 1/ 96/ 024/ 010
Særnavn Crixivan Crixivan Crixivan Crixivan Crixivan Crixivan Crixivan
Crixivan Crixivan Crixivan Crixivan Crixivan Crixivan Crixivan
Styrke 200 mg 200 mg 200 mg 400 mg 400 mg 400 mg 100 mg
200 mg 200 mg 200 mg 400 mg 400 mg 400 mg 100 mg
Lægemiddelform Kapsel, hård Kapsel, hård Kapsel, hård Kapsel, hård Kapsel, hård Kapsel, hård Kapsel, hård
Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard
Indgivelsesvej Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse
Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Emballage Flaske (HDPE) Flaske (HDPE) Flaske (HDPE) Flaske (HDPE) Flaske (HDPE) Flaske (HDPE) Flaske (HDPE)
bottle (HDPE) bottle (HDPE) bottle (HDPE) bottle (HDPE) bottle (HDPE) bottle (HDPE) bottle (HDPE)
Indhold 328, 1 mg 328, 1 mg 328, 1 mg 656, 1 mg 656, 1 mg 656, 1 mg 164, 0 mg
328.1 mg 328.1 mg 328.1 mg 656.1 mg 656.1 mg 656.1 mg 164.0 mg
Pakningsstørrelse 180 270 360 90 180 18 180
180 270 360 90 180 18 180
CRIXIVAN 100 mg hårde kapsler
CRIXIVAN 100 mg hard capsules
Hver hård kapsel indeholder indinavirsulfat svarende til 100 mg indinavir.
Each hard capsule contains indinavir sulphate corresponding to 100 mg of indinavir.
Hver 100 mg kapsel indeholder 37, 4 mg lactose.
Each 100 mg capsule contains 37.4 mg lactose.
Kapslerne er delvis gennemsigtige, hvide og prægede CRIXIVAN™ 100 mg i grønt.
The capsules are semi– translucent white and coded CRIXIVAN™ 100 mg in green.
CRIXIVAN er i kombination med antiretrovirale nukleosidanaloger indiceret til behandling af voksne, unge og børn fra 4 år, med HIV- 1 infektion.
CRIXIVAN is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV– 1 infected adults, adolescents, and children 4 years of age and older.
4. 4).
In adolescents and children, the benefit of indinavir therapy versus the increased risk of nephrolithiasis should particularly be considered (see section 4.4).
CRIXIVAN bør administreres af læger med erfaring i behandling af HIV- infektion.
CRIXIVAN should be administered by physicians who are experienced in the treatment of HIV infection.
5. 1).
When indinavir is administered as monotherapy resistant viruses rapidly emerge (see section 5.1).
Voksne Den anbefalede dosis af CRIXIVAN er 800 mg oralt hver 8. time.
Adults The recommended dosage of CRIXIVAN is 800 mg orally every 8 hours.
5. 2).
The suggestion is based on limited published data (see section 5.2).
Børn og unge (4 til 17 år) Anbefalet dosis CRIXIVAN for patienter i alderen 4- 17 år, er 500 mg/ m2 (dosis tilpasset udfra målt legemsoverfladeareal (LOA) baseret på højde og vægt) indtaget oralt hver 8. time (se tabel nedenfor).
Children and adolescents (4 to 17 years of age) The recommended dosage of CRIXIVAN for patients 4 to 17 years of age is 500 mg/ m2 (dose adjusted from calculated body surface area [BSA] based on height and weight) orally every 8 hours (see table below).
Denne dosis bør ikke overskride, hvad der svarer til en voksendosis på 800 mg hver 8. time.
This dose should not exceed the equivalent of the adult dose of 800 mg every 8 hours.
CRIXIVAN hårde kapsler bør kun gives til børn, som er i stand til at sluge hårde kapsler.
CRIXIVAN hard capsules should only be given to children who are able to swallow hard capsules.
5. 1 og 5. 2).
CRIXIVAN has not been studied in children under the age of 4 years (see section 5.1 and 5.2).
2 Pædiatrisk dosis (500 mg/ m2) administreret hver 8. time
2 Paediatric dose (500 mg/ m2) to be administered every 8 hours
Legems -
Body Surface Area (m2)
CRIXIVAN dosis
CRIXIVAN dose Every 8 hours (mg)
overfladeareal (m2) 0, 50 0, 75 1, 00 1, 25 1, 50
0.50 0.75 1.00 1.25 1.50
hver 8. time (mg) 300 400 500 600 800
300 400 500 600 800
Generel administrationsvejledning De hårde kapsler bør synkes hele.
General administration recommendations The hard capsules should be swallowed whole.
Alternativt kan CRIXIVAN administreres med et fedtfattigt, let måltid.
Alternatively, CRIXIVAN may be administered with a low– fat, light meal.
For at sikre tilstrækkelig hydrering, anbefales det at voksne drikker mindst 1, 5 liter væske i løbet af 24 timer.
To ensure adequate hydration, it is recommended that adults drink at least 1.5 litres of liquids during the course of 24 hours.
Det anbefales også at børn, der vejer mindre end 20 kg, drikker mindst 75 ml/ kg/ dag, og at børn som vejer 20 - 40 kg drikker mindst 50 ml/ kg/ dag.
It is also recommended that children who weigh less than 20 kg drink at least 75 ml/ kg/ day and that children who weigh 20 to 40 kg drink at least 50 ml/ kg/ day.
4. 4).
Medical management in patients with one or more episodes of nephrolithiasis must include adequate hydration and may include temporary interruption of therapy (e. g., 1 to 3 days) during the acute episode of nephrolithiasis or discontinuation of therapy (see section 4.4).
4. 5).
Special dosing considerations in adults A dosage reduction of CRIXIVAN to 600 mg every 8 hours should be considered when administering itraconazole or ketoconazole concurrently (see section 4.5).
Hos patienter med mild til moderat leversvigt forårsaget af cirrose, bør CRIXIVAN dosis reduceres til 600 mg hver 8. time.
In patients with mild– to– moderate hepatic impairment due to cirrhosis, the dosage of CRIXIVAN should be reduced to 600 mg every 8 hours.
5. 2).
The recommendation is based on limited pharmacokinetic data (see section 5.2).
4. 4).
Patients with severe hepatic impairment have not been studied; therefore, no dosing recommendations can be made (see section 4.4).
4. 4).
Safety in patients with impaired renal function has not been studied; however, less than 20% of indinavir is excreted in the urine as unchanged drug or metabolites (see section 4.4).
Både CRIXIVANs og ritonavirs hæmning af CYP3A4 kan medføre forhøjede plasmakoncentrationer af disse lægemidler, og kan dermed medføre alvorlige eller livstruende reaktioner.
Inhibition of CYP3A4 by both CRIXIVAN and ritonavir could result in elevated plasma concentrations of these medicines, potentially causing serious or life-threatening reactions.
4. 4).
CRIXIVAN with or without ritonavir should not be administered concurrently with amiodarone, terfenadine, cisapride, astemizole, alprazolam, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), pimozide, ergot derivatives, simvastatin or lovastatin (see section 4.4).
4. 5).
Concurrent use of indinavir with herbal preparations containing St John’ s wort (hypericum perforatum) is contraindicated (see section 4.5).
3 Desuden bør indinavir med ritonavir ikke administreres samtidigt med alfuzosin, mepiridin, piroxicam, propoxifen, bepridil, encainid, felcanid, propafenon, quinidin, fusidinsyre, clozapin, clorazepat, diazepam, estazolam og flurazepam.
3 In addition, indinavir with ritonavir should not be administered with alfuzosin, meperidine, piroxicam, propoxyphene, bepridil, encainide, flecanide, propafenone, quinidine, fusidic acid, clozapine, clorazepate, diazepam, estazolam and flurazepam.
4. 4).
Ritonavir should not be given with indinavir to patients with decompensated liver disease as ritonavir is principally metabolized and eliminated by the liver (see section 4.4).
Nefrolitiasis og tubulointerstitial nefritis Der er set nefrolitiasis hos voksne og pædiatriske patienter ved behandling med indinavir.
Nephrolithiasis and tubulointerstitial nephritis Nephrolithiasis has occurred with indinavir therapy in adult and paediatric patients.
Hyppigheden af nefrolitiasis er højere for pædiatriske patienter end for voksne patienter.
The frequency of nephrolithiasis is higher in paediatric patients than in adult patients.
1 - 3 dage) under den akutte episode med nefrolitiasis eller seponering af behandling overvejes.
If signs and symptoms of nephrolithiasis, including flank pain with or without haematuria (including microscopic haematuria) occur, temporary interruption of therapy (e. g. for 1– 3 days) during the acute episode of nephrolithiasis or discontinuation of therapy may be considered.
Pædiatriske patienter, som får lændesmerter, bør undersøges for mulig nefrolitiasis.
Paediatric patients who experience flank pain should be evaluated for the possibility of nephrolithiasis.
Langtidseffekterne af nefrolitiasis hos pædiatriske patienter er ikke kendte.
The long– term effects of nephrolithiasis in paediatric patients are unknown.
4. 2 og 4. 8).
Adequate hydration is recommended in all patients on indinavir (see section 4.2 and 4.8).
Der er set tilfælde af interstitial nefritis med medullær kalcifikation og kortikal atrofi hos patienter med asymptomatisk svær leukocyturi (> 100 celler/ højt styrkefelt).
Cases of interstitial nephritis with medullary calcification and cortical atrophy have been observed in patients with asymptomatic severe leucocyturia (> 100 cells/ high power field).
Hos patienter med forhøjet risiko, som eksempelvis børn, bør screening af urin overvejes.
In patients at increased risk such as children, urinary screening should be considered.
Hvis der findes vedholdende, svær leucocyturi, kan yderligere undersøgelser være nødvendige.
If persistent severe leucocyturia is found, further investigation might be warranted.
Lægemiddelinteraktioner Indinavir bør anvendes med forsigtighed sammen med andre lægemidler, som er potente CYP3A4 induktorer.
Medicinal product interactions Indinavir should be used cautiously with other medicinal products that are potent inducers of CYP3A4.
4. 5).
Co– administration may result in decreased plasma concentrations of indinavir and as a consequence an increased risk for suboptimal treatment and facilitation of development of resistance (see section 4.5).
Baseret på en interaktionsundersøgelse med lopinavir/ ritonavir anbefales kombinationen af rosuvastatin og proteasehæmmere ikke.
Based on an interaction study with lopinavir/ ritonavir, combination of rosuvastatin and protease inhibitors is not recommended.
4. 5).
The interaction of indinavir or indinavir/ ritonavir with pravastatin or fluvastatin is not known (see section 4.5).
4. 5).
Co– administration of CRIXIVAN with sildenafil, tadalafil and vardenafil (PDE5 inhibitors) are expected to substantially increase the plasma concentrations of these compounds and may result in an increase in PDE5 inhibitor– associated adverse events, including hypotension, visual changes, and priapism (see section 4.5).
Akut hæmolytisk anæmi Der er rapporteret akut hæmolytisk anæmi, hvilket i nogle tilfælde var alvorlig og hurtigt progredierende.
Acute haemolytic anaemia Acute haemolytic anaemia has been reported which in some cases was severe and progressed rapidly.
4 Der er rapporteret debuterende diabetes mellitus, hyperglykæmi eller forværring af eksisterende diabetes mellitus hos patienter i behandling med proteasehæmmere (PIere).
4 Hyperglycaemia New onset diabetes mellitus, hyperglycaemia or exacerbation of existing diabetes mellitus has been reported in patients receiving protease inhibitors (PIs).
Hos nogle af disse patienter var hyperglykæmien alvorlig og i nogle tilfælde også associeret med ketoacidose.
In some of these the hyperglycaemia was severe and in some cases also associated with ketoacidosis.
Mange af disse patienter led i forvejen af diffuse symptomer, hvoraf nogle var behandlingskrævende med præparater, der har været associeret med udviklingen af diabetes mellitus eller hyperglykæmi.
Many patients had confounding medical conditions, some of which required therapy with agents that have been associated with the development of diabetes mellitus or hyperglycaemia.
Omfordeling af fedt Antiretroviral kombinationsbehandling er hos HIV- patienter blevet associeret med omfordeling af kropsfedt (lipodystrofi).
Fat redistribution Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV patients.
Langtidskonsekvenserne heraf er i øjeblikket ukendte.
The long term consequences of these events are currently unknown.
Det er blevet antaget, at der er en forbindelse mellem visceral lipomatose og PIere samt lipoatrofi og nukleoside reverse transcriptasehæmmere (NRTIere).
A connection between visceral lipomatosis and PIs and lipoatrophy and nucleoside reverse transcriptase inhibitors (NRTIs) has been hypothesised.
En højere risiko for lipodystrofi er blevet sat i forbindelse med individuelle faktorer som højere alder, og med lægemiddelrelaterede faktorer som længere antiretroviral behandlingstid og ledsagende metaboliske forstyrrelser.
A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances.
Leversygdom Sikkerhed og effekt af indinavir er ikke fastlagt hos patienter med signifikant underliggende leversygdomme.
Liver disease The safety and efficacy of indinavir has not been established in patients with significant underlying liver disorders.
Patienter med kronisk hepatitis B eller C, og som har modtaget antiretroviral kombinationsbehandling, har øget risiko for at få alvorlige og potentielt fatale leverbivirkninger.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
Sikkerhed og effekt for indinavir/ ritonavir er ikke fastsat hos patienter med betydende underliggende leversygdomme og bør ikke anvendes til denne patientpopulation.
The safety and efficacy of indinavir/ ritonavir has not been established in patients with significant underlying liver disorders and should not be used in this patient population.
Immunreaktiveringssyndrom Hos HIV- inficerede patienter med svær immuninsufficiens kan der ved påbegyndelse af antiretroviral kombinationsbehandling (CART) opstå en inflammatorisk reaktion på asymptomatiske eller residuale opportunistiske patogener, som kan forårsage alvorlige kliniske tilstande eller forværring af symptomer.
Immune Reactivation Syndrome In HIV-infected patients with sever immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Relevante eksempler er cytomegalovirus retinitis, generaliserede og/ eller fokale mycobakterielle infektioner og pneumocystis carinii pneumoni.
Relevant examples are cytomegalovirus retinitis, generalised and/ or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Patienter med samtidigt eksisterende tilstande Hos patienter med hæmofili A og B har der været flere rapporter om øget blødningstendens med spontane hudblødninger og ledblødninger under behandling med PIere.
Patients with coexisting conditions There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with PIs.
Hos patienter med mild til moderat leverinsufficiens på grund af cirrose vil det være nødvendigt at reducere indinavirdosis på grund af nedsat metabolisme af indinavir (se pkt.
Patients with mild– to– moderate hepatic insufficiency due to cirrhosis will require a dosage reduction of indinavir due to decreased metabolism of indinavir (see section 4.2).
4. 2).
5 Safety in patients with impaired renal function has not been studied; however, less than 20% of indinavir is excreted in the urine as unchanged drug or metabolites (see section 4.2).
800 mg dosis (maksimal enkeltdosis).
Lactose This medicinal product contains 299.2 mg of lactose in each 800-mg dose (maximum single dose).
Denne mængde er sandsynligvis ikke nok til at inducere symptomer på lactoseintolerance (mælkeallergi).
This quantity is not likely to induce symptoms of lactose intolerance (milk intolerance).
Patienter med de sjældne arvelige problemer galactoseintolerance, Lapp lactosemangel eller glucose - galactosemalabsorption bør ikke tage dette lægemiddel.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Om disse resultater er af relevans for pædiatriske patienter vides ikke.
The relevance of the results from these studies in paediatric patients is unknown.
Indinavirs metabolisme er medieret af cytokrom P450- enzymet CYP3A4.
The metabolism of indinavir is mediated by the cytochrome P450 enzyme CYP3A4.
Derfor kan andre substanser, der enten metaboliseres ad samme vej eller modificerer CYP3A4- aktivitet, influere på indinavirs farmakokinetik.
Therefore, other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of indinavir.
CRIXIVAN, med eller uden ritonavir, bør ikke administreres samtidigt med amiodaron, terfenadin, cisaprid, astemizol, alprazolam, triazolam, midazolam givet peroralt (mht. forsigtighed ved parenteralt administreret midazolam, se tabel 1 og 2 nedenfor), pimozid, ergotderivater, simvastatin eller lovastatin.
CRIXIVAN with or without ritonavir should not be administered concurrently with amiodarone, terfenadine, cisapride, astemizole, alprazolam, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see Table 1 and 2 below), pimozide, ergot derivatives, simvastatin or lovastatin.
Samtidig brug af indinavir og rifampicin eller naturlægemidler med perikon (hypericum perforatum) er kontraindiceret.
Concurrent use of indinavir with rifampicin or herbal preparations containing St John’ s wort (hypericum perforatum) is contraindicated.
De lægemidler, der nævnes ovenfor, gentages ikke i tabel 1 og 2, medmindre specifikke interaktionsdata er tilgængelige.
Drugs listed above are not repeated in Table 1 and 2 unless specific interaction data is available.
4. 2 og 4. 3.
Refer also to sections 4.2 and 4.3.
6 Tabel 1.
Table 1.
Interaktioner og dosisrekommandationer sammen med andre lægemidler – IKKE - BOOSTET INDINAVIR
Interactions and dose recommendations with other medical products – UNBOOSTED INDINAVIR
Interaktioner mellem indinavir og andre lægemidler fremgår af tabellerne nedenfor (stigning er vist som "↑", fald som "↓", ingen ændring (≤ + / - 20%) som "↔", enkeltdosis som "SD", én gang dagligt som "QD", to gange dagligt som "BID", tre gange dagligt som "TID", og fire gange dagligt som "QID").
Interactions between indinavir and other medicinal products are listed in the tables below (increase is indicated as “↑”, decrease as “↓”, no change (≤ +/ - 20%) as “↔”, single dose as “ SD”, once daily as “ QD”, twice daily as “ BID”, three times daily as “ TID”, and four times as "QID").
Lægemidler i henhold til terapeutisk område ANTI- INFEKTIVA Antiretrovirale lægemidler NRTIer
6 Medicinal products by therapeutic areas ANTI-INFECTIVES Antiretrovirals NRTIs
Didanosin Formulering med buffer
Didanosine Formulation with buffer
Indinavir - og didanosinformuleringer, der indeholder buffer, bør administreres med mindst en times mellemrum på tom mave.
Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.